Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q15042

UPID:
RB3GP_HUMAN

ALTERNATIVE NAMES:
RAB3 GTPase-activating protein 130 kDa subunit; Rab3-GAP p130

ALTERNATIVE UPACC:
Q15042; A6H8Z3; C9J837; Q659F5; Q8TBB4

BACKGROUND:
RAB3GAP1, functioning as the catalytic component of the Rab3GAP complex, is essential for the inactivation of Rab3 proteins and the activation of RAB18, thereby playing a critical role in regulated exocytosis and ER structure maintenance. Its involvement in eye and brain development underscores its biological significance.

THERAPEUTIC SIGNIFICANCE:
The association of RAB3GAP1 with Warburg Micro syndrome 1 and Martsolf syndrome 2, due to gene variants, highlights its therapeutic potential. Targeting RAB3GAP1's pathway could offer novel treatment avenues for these genetic disorders, emphasizing the importance of further research into its functions and mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.